Janux Therapeutics (NASDAQ:JANX) Releases Earnings Results, Beats Estimates By $0.21 EPS

Janux Therapeutics (NASDAQ:JANX) announced its quarterly earnings data on Thursday. The company reported ($0.39) earnings per share for the quarter, topping the consensus estimate of ($0.60) by $0.21, FiscalAI reports. The company had revenue of $10.00 million for the quarter, compared to analysts’ expectations of $3.07 million.

Janux Therapeutics Price Performance

NASDAQ JANX traded down $2.18 during trading hours on Friday, hitting $26.48. The company had a trading volume of 1,750,098 shares, compared to its average volume of 1,196,176. The firm’s 50 day moving average is $25.11 and its 200 day moving average is $25.27. Janux Therapeutics has a fifty-two week low of $21.73 and a fifty-two week high of $71.71. The company has a market capitalization of $1.59 billion, a price-to-earnings ratio of -15.76 and a beta of 2.83.

Analyst Ratings Changes

A number of equities analysts have weighed in on JANX shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Janux Therapeutics in a research note on Wednesday, October 8th. Guggenheim initiated coverage on Janux Therapeutics in a research report on Wednesday, September 3rd. They issued a “buy” rating and a $72.00 target price on the stock. Raymond James Financial assumed coverage on Janux Therapeutics in a report on Friday, July 11th. They issued an “outperform” rating and a $65.00 target price on the stock. Stifel Nicolaus restated a “buy” rating and set a $45.00 price target on shares of Janux Therapeutics in a research note on Wednesday, September 10th. Finally, Wedbush restated an “outperform” rating and issued a $76.00 price objective on shares of Janux Therapeutics in a report on Friday. Two investment analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $79.17.

Insider Buying and Selling at Janux Therapeutics

In other news, insider Andrew Hollman Meyer sold 16,665 shares of the company’s stock in a transaction dated Tuesday, October 28th. The stock was sold at an average price of $30.06, for a total value of $500,949.90. Following the completion of the sale, the insider owned 82,139 shares of the company’s stock, valued at $2,469,098.34. This represents a 16.87% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 8.10% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. California State Teachers Retirement System grew its stake in Janux Therapeutics by 1.1% during the 2nd quarter. California State Teachers Retirement System now owns 37,139 shares of the company’s stock valued at $858,000 after purchasing an additional 404 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Janux Therapeutics by 11.5% during the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,866 shares of the company’s stock valued at $551,000 after buying an additional 2,463 shares during the last quarter. Tower Research Capital LLC TRC grew its position in shares of Janux Therapeutics by 175.5% during the second quarter. Tower Research Capital LLC TRC now owns 3,928 shares of the company’s stock worth $91,000 after buying an additional 2,502 shares in the last quarter. Osaic Holdings Inc. increased its stake in shares of Janux Therapeutics by 704.6% in the second quarter. Osaic Holdings Inc. now owns 3,468 shares of the company’s stock worth $80,000 after buying an additional 3,037 shares during the last quarter. Finally, AQR Capital Management LLC raised its holdings in Janux Therapeutics by 71.7% in the first quarter. AQR Capital Management LLC now owns 9,717 shares of the company’s stock valued at $262,000 after acquiring an additional 4,059 shares in the last quarter. Hedge funds and other institutional investors own 75.39% of the company’s stock.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.